The objective of the meeting was to provide information about the weight loss drugs known as the “titans of weight loss,” specifically the drugs Ozempic and Wegovy. The presenter aimed to explain the history and development of these drugs, their mechanism of action, their approval status in different countries, and their potential benefits and risks.
The presenter emphasized the importance of considering the individual’s health and weighing the potential benefits and risks before deciding to take the weight loss drugs. Lifestyle changes, such as diet and exercise, should also be considered as part of a comprehensive weight loss approach. The presenter offered additional resources and a zip file of references for those interested in further reading.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab (2022) 24(8):1553-1564. John P H Wilding, Rachel L Batterham, Melanie Davies, Luc F Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, Barbara M McGowan, Tugce Kalayci Oral, Julio Rosenstock, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Robert F Kushner; STEP 1 Study Group